ZyVersa Therapeutics induces warrant exercise for up to 12.1M shares; issues new warrants

ZyVersa Therapeutics, Inc.

Holder to exercise up to 12,121,213 existing warrants at reduced price (lower of that day's close or 5-day average) by Sep 18, 2023.
In exchange, ZyVersa issues new warrants to purchase same number of shares, exercisable at same reduced price starting 6 months after issuance for 5 years.
New warrants are unregistered, issued under Section 4(a)(2); existing warrant shares are registered.
A.G.P./Alliance Global Partners acts as financial advisor with 6% fee on gross proceeds.
Beneficial ownership blocker set at 4.99% or 9.99% per holder election.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.